Cancer drugs A to Z list

Esophageal Cancer Treatment

Transport to cancer treatment

During OCRA’s Advocacy Day this fall, we followed Chad Ramsey, OCRA’s VP of Policy, and Rachel P., a Patient Advocate with low-grade serous ovarian cancer (LGSOC), on their trip to Capitol Hill. Rachel met with representatives from her district in Arizona to discuss ovarian cancer research initiatives and share her story. Hear from Rachel and Chad about their experience and hopes for the future of ovarian cancer research. LGSOC is a rare form of ovarian cancer that tends to affect younger women

Sophie's LGSOC story part 3: I’ve completed chemo, the second part of my treatment journey. For me, there’s still more to come because your cancer journey doesn’t end after chemo, especially with my cancer, but for now, I am proud of how I have got through the past 7 months. From the moments I heard “I’m sorry, it’s cancer. You will need to have all your reproductive organs removed”, this moment was in the distance, not thinking about my end goal but focussing on each step to get there. Through

As we near LGSOC Awareness Day on September 9, we want to share this important message: There is no such thing as Too Young for Ovarian Cancer. To learn more and become an awareness partner, visit LGSOCawarenessday.org. #LGSOCAwarenessDay #LGSOCDay #LGSOC #ShareTheSignsSaveALife #OvarianCancerAwareness #weartealday #lowgradeserousovariancancer | STAAR Low-Grade Serous Ovarian Cancer

Dr. Weber on Side Effects of Dabrafenib/Trametinib in Melanoma | OncLive